Molecular Profiling, Precision Medicine, & Targeted Therapies for the Treatment of ALK Positive NSCLC

 
Share
 

Manage episode 220014011 series 1452688
By ReachMD. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Host: Alice T. Shaw, MD, PhD
The discovery of predictive biomarkers, such as sensitizing epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, ROS1 rearrangements, and BRAF V600E mutations has led to an improvement in overall survival and progression-free survival in non–small cell lung cancer (NSCLC) by identifying subgroups of patients who benefit from targeted treatment. Approximately 5% of patients with NSCLC have ALK gene rearrangements. One of the most noteworthy areas of progress is the development of effective ALK-targeting therapies to treat NSCLC, including crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib, with additional agents under development in ALK positive advanced NSCLC.

This activity will review ALK testing, current and emerging treatment options for ALK positive NSCLC, and recognition and management of adverse events associated with these treatments.

153 episodes